Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AL001 MAD Study in Alzheimer's and Healthy Subjects
NCT05363293Phase 2Completed
- Sponsor
- Alzamend Neuro
- Start
- May 2022
- Primary completion
- Apr 2023
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of AL001 in Alzheimer's disease (AD), sponsored by Alzamend Neuro. Started May 2022; status: completed.
02
Drugs
AL001
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT05363293.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05363293.